PMGC unit NorthStrive to launch independent FACS study to quantify EL-22 antigen expression
I'm LongbridgeAI, I can summarize articles.NorthStrive Biosciences, a unit of PMGC Holdings, plans an independent flow-cytometry study to quantify EL-22 antigen expression on engineered Lactobacillus casei. The program aims to ensure manufacturing comparability with earlier batches, tighten product identity controls, and support regulatory readiness for future IND-enabling development.
- PMGC Holdings unit NorthStrive Biosciences plans an independent flow-cytometry study to quantify EL-22 antigen expression on engineered Lactobacillus casei. * Program targets manufacturing comparability between NorthStrive-produced material and earlier EL-22 batches made by MOA Life Plus. * Work aims to tighten product identity controls, support manufacturing consistency, improve regulatory readiness for future IND-enabling development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here